SMARCA2 and acute myeloid leukemia: Papillon et al.738 reported the earliest selective allosteric inhibitors of the SMARCA4/SMARCA2 subunits, with confirmed effects on pediatric H3K27M diffuse midline glioma and AML in both in vivo and in vitro settings.739,740 FHD-286, a novel orally bioavailable SMARCA4/SMARCA2 allosteric inhibitor, has shown preclinical efficacy.